Psychopharmacology for the clinician. Treating depression with selective norepinephrine reuptake inhibitors.

To submit questions for this regular feature, please send them to the editors-in-chief at ac.amc@npj. Please include details of any relevant case and your name, address, telephone and fax numbers, as well as your email address. The information in this column is not intended as a definitive treatment strategy but as a suggested approach for clinicians treating patients with similar histories. Individual cases may vary and should be evaluated carefully before treatment is provided. Competing interests: Dr. Blier is a consultant with Biovail, Eli Lilly, Forest Laboratories and Lundbeck and is a contract employee with Forest Laboratories. He is in the speaker's bureau for Cyberonics, Eli Lilly, Forest Laboratories and Lundbeck and has received grant funding from Eli Lilly and Forest Laboratories.